Fierce Pharma March 26, 2024
Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to more than 250 workers at the biotech’s headquarters in California.
In a Worker Adjustment and Retraining Notification Act (WARN) notice, BMS said it’s laying off 252 staffers at 3545 Cray Court in San Diego. That’s the headquarters of cancer specialist Mirati, according to that company’s financial filings.
The cuts come shortly after the companies closed their M&A deal in late January. Back in October, BMS agreed to pay $4.8 billion for the commercial biotech, plus $1 billion through a contingent value right tied to the regulatory advancement of a pipeline drug.
With the Mirati buyout, BMS picked up the FDA-approved non-small cell...
Today's Sponsors
Today's Sponsor